Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.34 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: osoresnontrine, tovinontrine, pentoxifylline +3 | 1.00 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 0932
Sealed predictions
- PDE9A in dopamine neurons, braak-0.13 (p 0.733) → -0.15 (p 0.697)receipt 0940
Swarm cases
receipt 0940: PDE9A in dopamine neurons, braak
- power
- full sample -0.31 (p 0.204, n 18), 95% CI -0.68 to +0.18. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.29 (p 0.239, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.44 (p 0.067, n 18). could be the mix.
- skeptic
- leave-one-out range -0.43 to -0.22, sign flips 0; without severely affected donors -0.31 (p 0.204, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.67 (p 0.0025, n 18) vs -0.31 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PDE9A in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up PDE9A · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.30 p 0.286 (needs p < 0.0014)
Receipts
loading the receipts